We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Portable qPCR Platform Enables Faster, Better, Low-Cost Near-Patient Molecular Diagnosis

By HospiMedica International staff writers
Posted on 13 Nov 2022
Print article
Image: Pixl Real-time PCR Platform (Photo courtesy of BioGX)
Image: Pixl Real-time PCR Platform (Photo courtesy of BioGX)

The point-of-care molecular diagnostics space seems to have gotten more crowded during COVID. Now, a portable molecular diagnostics platform with 16-well capabilities differentiates itself from most competitors who use single cartridge or single test formats.

BioGX’s (Birmingham, AL, USA) Pixl is a benchtop 4-channel, 16-well, RT-PCR instrument that supports rapid turnaround times for batches of up to 16 samples, with integrated results interpretation on a device with the compact footprint of a touchpad. The high-performance open system real-time PCR platform is equipped with 4-optical channel direct imaging fluorescence, ultra-low-light CMOS bio-imager sensor and fast Peltier-powered thermal cycler to enable reliable and accurate molecular diagnostic testing. The compact device is the ultimate solution for applications where portability, minimal space and fast turnaround times are required.

Between 1 and 16 individual patient samples can be batch tested in less than 1 hour, ensuring a fast turnaround time in any environment. With intuitive results analysis software and built-in touchscreen functionality, the portable qPCR real-time PCR platform adapts to any testing environment and boasts turnaround times of less than an hour. Pixl is a lightweight yet rugged device, with no internal moving parts that serves as a great advantage for any testing facility which requires effective molecular testing on the move. A 4-optical channel, multiplex capability, with commonly adopted excitation and emission range and filters allow for unparalleled performance with commonly used fluorophores. The system is also potentially compatible with the BioGX suite of lyophilized molecular diagnostics assays.

With the Pixl, customers can run tests on 16 patient samples, or up to 16 different tests on a single sample, with as many as four targets per test, if needed. The Pixl can report out Ct values, or it can be set up to call positive or negative test results. BioGX’s software enables sample accessioning and can create reports that can be customized to adapt to a customer’s laboratory information system. BioGX plans to target hospital and reference labs as well as physician offices with the system. The firm’s suite of lyophilized tests may also engender a particular advantage in the POC space, as a large menu could differentiate Pixl from the competition. While the current 16-well Pixl can detect four targets per sample, a future version of the 16-well platform will be able to detect five to six targets.

BioGX has announced the Ex-US commercial release of its portable Pixl qPCR real-time PCR platform for use with BioGX CE-IVD marked assays, enabling global access and complementing the recent US FDA EUA expanded use of Xfree COVID-19 Direct RT-PCR on the Pixl. The platform was previously CE-IVD marked and can be used with other BioGX CE-IVD marked assays including Xfree COVID-19 (N1-gene) Direct RT-PCR, Xfree COVID-19 (N1/RdRp), Flu A, Flu B, and Xfree Group A Streptococcus. BioGX will soon make additional syndromic tests available on the Pixl platform from its large menu of lyophilized multiplex assays, including the Research Use Only (RUO) Direct-Sample assays: Xfree Human Monkeypox (hMPXV), Xfree HSV1/HSV2/VZV and Xfree Treponema pallidum (Syphilis). The Xfree assay format is compatible with most commonly used transport/collection media types and can be validated with a wide variety of patient sample collections.

"Pixl, combined with our unique Xfree chemistry, offers a low-cost direct-sample-to-answer PCR solution on a portable, compact device. pixl will provide broader access to clinical laboratories for decentralized PCR testing, enabling faster, better, low-cost near-patient molecular diagnostics," said Shazi Iqbal, Ph.D., CEO of BioGX.

Related Links:
BioGX

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Anesthesia Cart
UMGSA-33369-VIL

Print article

Channels

Critical Care

view channel
Image: A machine learning tool can identify patients with rare, undiagnosed diseases years earlier (Photo courtesy of 123RF)

Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs

Patients suffering from rare diseases often endure extensive delays in receiving accurate diagnoses and treatments, which can lead to unnecessary tests, worsening health, psychological strain, and significant... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more